P Dang

VP-16 and cisplatin as first-line therapy for small-cell lung cancer.

William K. Evans, Frances A. Shepherd, Ronald Feld et al. · Journal of Clinical Oncology · 1985 · 314 citations

Medicine, Oncology, Pharmacology +13

Patients with chronic myeloid leukemia who maintain a complete molecular response after stopping imatinib treatment have evidence of persistent leukemia by DNA PCR

David M. Ross, Susan Branford, John F. Seymour et al. · Leukemia · 2010 · 267 citations

Medicine, Molecular Biology, Oncology +15

Chemotherapy following surgery for stages IE and IIE non-Hodgkin's lymphoma of the gastrointestinal tract.

Frances A. Shepherd, William K. Evans, G Kutas et al. · Journal of Clinical Oncology · 1988 · 73 citations

Medicine, Oncology, Surgery +12

The clinical significance of ABCB1 overexpression in predicting outcome of CML patients undergoing first-line imatinib treatment

Laura N Eadie, P Dang, V. A. Saunders et al. · Leukemia · 2016 · 68 citations

Medicine, Hematology, Molecular Biology +7

Chronic phase chronic myeloid leukemia patients with low OCT-1 activity randomized to high-dose imatinib achieve better responses and have lower failure rates than those randomized to standard-dose imatinib

Deborah L. White, Jerald P. Radich, Simona Soverini et al. · Haematologica · 2011 · 63 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +10